MX2010010209A - 4-hidroxipirimidina-5-carboxamidas sustituidas. - Google Patents

4-hidroxipirimidina-5-carboxamidas sustituidas.

Info

Publication number
MX2010010209A
MX2010010209A MX2010010209A MX2010010209A MX2010010209A MX 2010010209 A MX2010010209 A MX 2010010209A MX 2010010209 A MX2010010209 A MX 2010010209A MX 2010010209 A MX2010010209 A MX 2010010209A MX 2010010209 A MX2010010209 A MX 2010010209A
Authority
MX
Mexico
Prior art keywords
hydroxypyrimidine
substituted
carboxamides
conditions
relates
Prior art date
Application number
MX2010010209A
Other languages
English (en)
Inventor
Matthew J Clements
John S Debenham
Jeffrey J Hale
Christina B Madsen-Duggan
Thomas F Walsh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2010010209A publication Critical patent/MX2010010209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a 4-hidroxipirimidina-5-carboxami das sustituidas útiles como inhibidores de prolilhidroxilasas de HIF para tratar anemia y afecciones similares.
MX2010010209A 2008-03-18 2009-03-09 4-hidroxipirimidina-5-carboxamidas sustituidas. MX2010010209A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6986408P 2008-03-18 2008-03-18
US19291808P 2008-09-23 2008-09-23
PCT/US2009/036501 WO2009117269A1 (en) 2008-03-18 2009-03-09 Substituted 4-hydroxypyrimidine-5-carboxamides

Publications (1)

Publication Number Publication Date
MX2010010209A true MX2010010209A (es) 2010-10-05

Family

ID=40627533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010209A MX2010010209A (es) 2008-03-18 2009-03-09 4-hidroxipirimidina-5-carboxamidas sustituidas.

Country Status (13)

Country Link
US (1) US8278304B2 (es)
EP (1) EP2257539B1 (es)
JP (1) JP5557832B2 (es)
CN (1) CN102036981B (es)
AR (1) AR070925A1 (es)
AU (1) AU2009225869B2 (es)
CA (1) CA2718528C (es)
CL (1) CL2009000639A1 (es)
ES (1) ES2524883T3 (es)
MX (1) MX2010010209A (es)
PE (1) PE20091627A1 (es)
TW (1) TW200944511A (es)
WO (1) WO2009117269A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2531354C2 (ru) 2008-04-28 2014-10-20 Янссен Фармацевтика Нв Бензоимидазолы как ингибиторы пролилгидроксилазы
JP2011528341A (ja) * 2008-07-18 2011-11-17 武田薬品工業株式会社 ベンズアゼピン誘導体及びそれらのヒスタミンｈ３拮抗薬としての使用
JP5643233B2 (ja) * 2009-02-10 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン
CA2766056A1 (en) * 2009-06-30 2011-01-06 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
EP2448584B1 (en) * 2009-06-30 2014-12-31 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
AR077999A1 (es) * 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
WO2011048525A1 (en) * 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
SI2492266T1 (sl) * 2009-10-21 2015-12-31 Daiichi Sankyo Company, Limited Derivat 5-hidroksipirimidin-4-karboksamida
AR079851A1 (es) * 2010-01-08 2012-02-22 Takeda Pharmaceutical Derivados de benzazepina para tratamiento de desordenes en el sistema nervioso central
US9006433B2 (en) 2010-04-21 2015-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
WO2012021830A1 (en) 2010-08-13 2012-02-16 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
EP2630122B1 (en) * 2010-10-18 2016-11-30 RaQualia Pharma Inc Arylamide derivatives as ttx-s blockers
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
CN103906733A (zh) * 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
WO2013036676A1 (en) 2011-09-06 2013-03-14 New York Blood Center, Inc. Hiv inhibitors
WO2013040790A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2758058B1 (en) * 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituted pyrimidines
US9079930B2 (en) 2011-09-23 2015-07-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013040789A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
BR112014009910B1 (pt) 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica
ES2649905T3 (es) 2012-03-30 2018-01-16 Daiichi Sankyo Company, Limited Derivado de ácido (2-heteroarilamino)succínico
CN103450194B (zh) * 2012-06-05 2015-07-08 首都医科大学 四氢-β-咔啉-3-甲酰脂肪链胺、其制备、纳米结构、免疫抑制作用及应用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
PT2978752T (pt) * 2013-03-29 2018-03-09 Takeda Pharmaceuticals Co Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e o seu uso como inibidores de phd
KR20160100329A (ko) 2013-12-20 2016-08-23 3-브이 바이오사이언시스, 인코포레이티드 지질 합성의 헤테로사이클릭 조절물질 및 이들의 조합물
JP2017114765A (ja) * 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物
EP3194030B1 (en) 2014-09-19 2019-11-06 New York Blood Center, Inc. Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv
JP6770511B2 (ja) * 2014-09-29 2020-10-14 ザ スクリプス リサーチ インスティテュート 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター
WO2016054804A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
WO2020156571A1 (zh) * 2019-02-02 2020-08-06 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
GB201908511D0 (en) * 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
CA3193204A1 (en) * 2020-09-25 2022-03-31 Shanghai Meiyue Biotech Development Co., Ltd. Pyrimidine carboxamide compound and application thereof
EP4365162A3 (en) 2020-12-21 2024-10-09 Intervet International B.V. A process for the preparation of n-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
BR112023025850A2 (pt) 2021-08-10 2024-03-05 Abbvie Inc Inibidores da nicotinamida ripk1
EP4413000A1 (en) 2021-10-04 2024-08-14 FoRx Therapeutics AG N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
GB202301059D0 (en) * 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors
GB202301050D0 (en) * 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD Inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2853220A1 (de) * 1978-12-09 1980-07-03 Hoechst Ag Neue amino-pyrimidin-carbanilide, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
EP0557879B1 (de) * 1992-02-22 1997-01-08 Hoechst Aktiengesellschaft 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
MY123528A (en) * 1999-09-16 2006-05-31 Mitsubihsi Tanabe Pharma Corp Aromatic nitrogen-containing 6-membered cyclic compounds.
US7087597B1 (en) * 1999-10-12 2006-08-08 Takeda Pharmaceutical Company Limited Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
CA2413702A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
EP1361879A1 (en) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
BRPI0415860A (pt) * 2003-10-31 2007-01-09 Warner Lambert Co pirimidinas como inibidores de fosfoinositìdeo 3-quinases (pi3k)
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
AU2006290465A1 (en) 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
BRPI0620668A2 (pt) * 2005-12-14 2011-11-22 Du Pont composto da fórmula 1, composição que compreende composto, composição de controle de pragas invertebradas, composição de pulverização, composição de isca, dispositivo de armadilha, métodos de controle de pragas invertebradas, método de controle de baratas, formigas ou cupins e método de proteção de sementes contra pragas invertebradas
US7928120B2 (en) * 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
US20090176825A1 (en) * 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
EP3026044B8 (en) * 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
AR062677A1 (es) * 2006-09-08 2008-11-26 Novartis Ag Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden

Also Published As

Publication number Publication date
JP2011515402A (ja) 2011-05-19
AR070925A1 (es) 2010-05-12
CA2718528C (en) 2016-10-25
TW200944511A (en) 2009-11-01
EP2257539A1 (en) 2010-12-08
US20090239876A1 (en) 2009-09-24
US8278304B2 (en) 2012-10-02
AU2009225869A1 (en) 2009-09-24
CN102036981B (zh) 2015-04-08
AU2009225869B2 (en) 2014-01-23
WO2009117269A1 (en) 2009-09-24
EP2257539B1 (en) 2014-09-10
CL2009000639A1 (es) 2009-07-17
ES2524883T3 (es) 2014-12-15
JP5557832B2 (ja) 2014-07-23
PE20091627A1 (es) 2009-10-30
CN102036981A (zh) 2011-04-27
CA2718528A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
MX2010010209A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
WO2008130600A3 (en) Quinolones and azaquinolones that inhibit prolyl hydroxylase
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
HRP20141038T1 (en) Benzoimidazoles as prolyl hydroxylase inhibitors
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
MX2011009568A (es) Inhibidores de la rho cinasa.
IL212762A0 (en) Thiochromene derivatives as hif hydroxylase inhibitors
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
GB2471806A (en) Compositions and methods for treating viral infections
AU2012289429A8 (en) Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
MX354402B (es) Inhibidores de molecula pequeña del dominio de homologia de pleckstrin y metodos para usar los mismos.
EP2326178A4 (en) INHIBITORS OF PROLYL-HYDROXYLASE
EA201000915A1 (ru) Ингибиторы пролилгидроксилазы
HK1168346A1 (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
TW200640924A (en) VEGF-R2 inhibitors and methods
MX2011013878A (es) 4-hidroxipirimidina-5-carboxamidas sustituidas.
EP2240178A4 (en) PROLYLHYDROXYLASEHEMMER
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EP2224926A4 (en) INHIBITORS OF PROLYL HYDROXYLASES
WO2008137084A3 (en) Diazaquinolones that inhibit prolyl hydroxylase activity
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
EP2273879A4 (en) PROLYLHYDROXYLASEHEMMER
EP2326179A4 (en) PROLYLHYDROXYLASEHEMMER
WO2010042636A3 (en) Telomerase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FA Abandonment or withdrawal